Navigation Links
New knowledge on the pharmacology of dopamine stabilizers
Date:2/24/2012

A study from Karolinska Institutet in Sweden shows that a new drug for Huntington's disease pridopidine or dopamine stabiliser ACR16 might operate via previously unknown mechanisms of action. Researchers have found that at very low concentrations, ACR16 binds to the sigma-1 receptor, a protein in the brain important to neuronal function and survival. This new knowledge can be used to develop future treatments for schizophrenia, involuntary Parkinsonian tremors and neurodegenerative diseases.

"It's conceivable that some of the beneficial effects of dopamine stabilisers are mediated via the sigma-1 receptor," says principal investigator Daniel Marcellino of the Department of Neuroscience. "Our results suggest a formerly overlooked aspect of dopamine stabiliser pharmacology."

Dopamine stabilisers are a new class of drug substance originally developed by Swedish Nobel laureate Professor Arvid Carlsson. In clinical trials, these substances have revealed promising results against neurological and neuropsychiatric conditions that currently lack suitable treatment, such as schizophrenia and the dyskinesia (involuntary tremors) caused as an adverse effect of Parkinson's drugs.

Pridopidine or dopamine stabiliser ACR16 (also known as Huntexil), is in an advanced phase of clinical trials (phase III) for the relief of the motor symptoms of Huntington's disease, an incurable disease caused by neuronal degeneration in certain parts of the brain. The disease, which is hereditary, is characterised by motor and subsequent psychiatric disorders, leading to a protracted death. There is currently only one drug registered for the relief of Huntington's symptoms, but as it has several adverse effects there is a strong demand for alternative treatment options.

Dopamine stabilisers are thought to exert their beneficial effects primarily via the dopamine D2 receptor, which is a well-known site of action for drugs for Parkinson's disease and schizophrenia. However, in a study published recently in the scientific journal Molecular Psychiatry, researchers at Karolinska Institutet have shown that ACR16 and another dopamine stabiliser (-)-OSU6162 also bind to the sigma-1 receptor in low concentrations.

"We found that ACR16 binds to the sigma-1 receptor at concentrations 100 times lower than those reported for interaction with the D2 receptor," says Dr Marcellino. "This is extremely interesting since experimental studies have shown that sigma-1 receptor ligands have positive effects in schizophrenia and protect against cell death in neurodegenerative conditions."


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related biology news :

1. Closing the gap: Journal launch brings together wound-healing knowledge
2. New scientific knowledge on juvenile diabetes
3. Researchers advance knowledge of little nano-machines in our body
4. Wallace S. Broecker wins the BBVA Foundation Frontiers of Knowledge Award in Climate Change
5. Federal scientists recognized for contributions to knowledge of bird ecology and habitat
6. Village bird study highlights loss of wildlife knowledge from one
7. German Research Minister Schavan: Rapid knowledge transfer can safe lives
8. The BBVA Foundation presents its Frontiers of Knowledge Awards
9. Peter Reich, BBVA Foundation Frontiers of Knowledge Award in Ecology
10. Studies improve knowledge of underlying brain changes caused by addiction
11. Technique finds gene regulatory sites without knowledge of regulators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: